Financial Report: Merck

Merck
 
2Q Revenues: $9.8 billion (-11%)

2Q Earnings: $687 million (earnings were $2 billion 2Q14)

YTD Revenues: $19.2 billion (-9%)

YTD Earnings: $1.6 billion (-56%)

Comments: Pharmaceutical sales were $8.6 billion, down 6% in the quarter. JANUVIA sales were $1.6 billion, up 1%. ZETIA / VYTORIN sales were down 16% to $955 million. GARDASIL sales were up 4% to $427 million. ISENTRESS sales dropped 17% to $375 million due to timing of tender purchases in the emerging markets and volume declines in the U.S. R&D expenses were $1.6 billion in the quarter, down 2%. Results include a 7% negative impact from foreign exchange and a 7% unfavorable impact from the divestiture of the Consumer Care business, partially offset by the acquisition of Cubist Pharmaceuticals.